Genome Research ( ) publishes a second special issue highlighting advances in long-read sequencing applications in ...

Now, an international research team from Japan, Taiwan, and Denmark revealed that Penghu 1 was derived from a male Denisovan by sequencing its bone and tooth proteins. The molecular identification of ...

Advancements in long-read sequencing technology have accelerated the study of large structural variants (SVs). We created a curated, publicly available, multi-ancestry S ...

In the default model, the graph representing each individual enhancer can be arbitrarily complicated. To show how the ABC Score formula can arise from the default model, we need to impose the further ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The inflation rate in Germany, measured as the year-on-year change in the consumer price index (CPI), stood at +2.2% in March 2025. The inflation rate was +2.3% in both February and January 2025, and ...

Novo's obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.